Nicotinamide Riboside Dampens Interferon Gene Signatures in Ataxia-Telangiectasia Patients

Ataxia-Telangiectasia (A-T) is a severe multisystem disorder characterized by immunodeficiency and progressive cerebellar ataxia, stemming from a loss of A-T mutated (ATM) protein activity. ATM is crucial for DNA damage responses, and its dysfunction leads to persistent activation of PARP1, which depletes intracellular NAD+. This NAD+ depletion impairs numerous cellular signaling pathways, creating a strong mechanistic rationale for NAD+ augmentation therapy. Current treatments for Ataxia-Telangiectasia primarily manage symptoms, highlighting the urgent need for disease-modifying strategies that address the underlying molecular pathology.

This study reports on a 24-month clinical trial where Nicotinamide Riboside (NR) was administered to Ataxia-Telangiectasia patients. The researchers performed longitudinal transcriptome profiling on peripheral blood mononuclear cells (PBMCs) to comprehensively define the molecular signatures of A-T and to assess pathway-level responses to NAD+ augmentation. This molecular analysis aimed to correlate with previously observed clinical improvements in coordination and eye movements in these patients, providing a deeper understanding of NR's therapeutic effects.

A-T patients exhibited reproducible transcriptomic alterations, specifically involving immune, vascular, and inflammatory pathways, establishing systemic molecular signatures of the disease. Crucially, NAD+ augmentation with Nicotinamide Riboside was associated with a significant suppression of interferon response genes. This dampening of interferon signaling was a key finding, indicating a direct molecular mechanism by which NR may exert its therapeutic effects. Furthermore, the modulation of these gene networks correlated with the observed neurological improvements in the A-T patients, suggesting a link between reduced inflammation and better clinical outcomes. The study identified potential blood-based biomarkers that reflect both disease processes and the therapeutic response to NR.

NAD+ augmentation with Nicotinamide Riboside was associated with suppression of interferon response genes and modulation of networks correlated with neurological improvement in Ataxia-Telangiectasia patients.